Dolatrox HCC Syringe 3ml

Dolatrox HCC

Dolatrox hcchcc È a medical device with CE mark in compliance with the MDD 93/42 / EEC directive and subsequent amendments and additions, containing hyaluronic acid obtained by fermentation and not chemically modified, chondroitin sulphate of marine origin and cyclodextrin.
Dolatrox hcchcc È a clear, sterile, non-pyrogenic and viscoelastic solution supplied in a 3 ml syringe.
Hyaluronic acid is; a natural polysaccharide present in many human tissues, in particular in the synovial fluid, and acts in the joints both as a lubricant of cartilages and ligaments and as a shock absorber.
According to many studies, injections of hyaluronic acid in joints affected by osteoarthritis restore viscosity; and elasticity of the synovial fluid, with a consequent alleviation of pain and an improvement in mobility; of the joint.
Chondrotin sulfate is; a high molecular weight glycosaminoglycan which is one of the essential building blocks of articular cartilage.
In vitro, chondroitin sulfate has demonstrated the ability; to inhibit hyaluronidases, enzymes that degrade hyaluronic acid by hydrolyzing its bonds.
Cyclodextrins are cyclic oligosaccharides capable of improving solubility; in water of some substances improving their stability; and changing the state of aggregation from liquid to viscous.
Thanks to the capacity; viscosifier of cyclodextrins, the solution of hyaluronic acid and chondroitin sulfate so Ì obtained has physical characteristics such as to guarantee a better efficacy. Dolatrox hcchcc acts only at the level of the joint where it is injected, without exerting any systemic action.

Directions for use
Remove any joint effusion before injecting Dolatrox hcchcc; the same needle must be used for effusion removal and injection of Dolatrox hcchcc.
Remove the protective cap of the syringe paying particular attention to avoid contact with the opening.
Firmly screw the 18 to 22 G diameter needle into the Luer-type locking collar to ensure a watertight seal.
Treat the site with an appropriate antiseptic solution before injection.
Inject Dolatrox hcchcc using aseptic technique. Inject only into the cavity; articulate.
Administration : Dolatrox hcchcc must be administered only once per therapy cycle; if necessary, the infiltration can Ò be repeated. The doctor will evaluate À the opportunity to administer another infiltration based on the patient's situation.

Components
Hyaluronic acid sodium salt (20 mg / ml), chondrotin sulphate of marine origin (20 mg / ml), hydroxypropyl-beta-cyclodextrin (10 mg / ml), sodium chloride, sodium phosphate and water for injections (to taste).

Warnings
The contents of the pre-filled syringe are; sterile. The syringe is packed in a sealed blister. The outer surface of the syringe is not sterile.
- Do not use Dolatrox hcchcc after the expiry date stated on the package.
- Do not use Dolatrox hcchcc if the package or syringe is open or damaged.
- The injection site must be on healthy skin.
- Do not inject by vascular route. Do not inject outside the cavity; joints, tissues or synovial capsules.
- Dolatrox hcchcc is not; been tested in pregnant or lactating women.
- Dolatrox hcchcc È disposable and must not be re-sterilized.
- Avoid the simultaneous administration of Dolatrox hcchcc with other products for intraarticular use in order to prevent any possible interaction.
- Do not administer Dolatrox hcchcc in the presence of abundant intraarticular effusion.
- Once the package has been opened, Dolatrox hcchcc must be used immediately and disposed of after use according to current regulations.
- Keep out of reach of children.
- As with any invasive treatment of the joint, it is recommended that the patient avoid all activities. physical intense for the first 2-3 days after injection.
Contraindications :
Dolatrox hcchcc should not be administered:
- to patients with ascertained sensitivity; hyaluronic acid and its compounds;
- in case of infection or skin disease near the injection site;
- if the joint is infected or strongly inflamed.
Side Effects :
Some transient side reactions may occur following the injection of Dolatrox hcchcc, such as pain, stiffness, warmth, redness or swelling . These secondary manifestations can be alleviated by applying ice to the treated joint. They usually disappear after a short time. If symptoms persist, seek medical attention. As with any invasive joint treatment, septic arthritis may occur if proper precautions are not observed during the injection or the injection site is not aseptic. The intraarticular injection should only be performed by a physician or in accordance with to local legislation.

Format
Glass syringe containing 3 ml of solution packed in a blister.
The contents of the syringe are; sterilized with moist heat.